FY 2027 IPPS Final Rule Breakdown

$8.049 billion. That is what CMS is paying out in uncompensated care in FY 2027. 🏥

That number alone tells you how much structural weight hospitals are already carrying before a single new mandate kicks in.

On July 31, 2026, CMS issued the FY 2027 Inpatient Prospective Payment System final rule. According to the National Law Review, it is scheduled for Federal Register publication on August 4, 2026. And it is packed with changes that every hospital finance, compliance, and strategy team needs to know right now.

Save this post. Here is the breakdown.

BEFORE vs. AFTER: THE RULE THAT CHANGED THE MOST

Old rule: FDA breakthrough device designation or qualified infectious disease product (QIDP) status gave manufacturers an alternative pathway to qualify for Medicare new technology add-on payments (NTAP) and outpatient transitional pass-through payments, without meeting all three standard eligibility criteria.

New rule: Those alternative pathways are repealed. All applicants, regardless of FDA breakthrough designation or QIDP status, must now demonstrate that their technology meets all three eligibility criteria. This applies to both inpatient and outpatient settings.

💡 This is the one most people are sleeping on. Breakthrough device designation was a fast lane. CMS just closed it.

KEY NUMBERS FROM THE FY 2027 IPPS FINAL RULE:

– 2.3% payment increase for hospitals that successfully participate in CMS reporting programs
– $8.049 billion in uncompensated care and supplemental payments for FY 2027, a 2.9% increase from the FY 2026 total of $7.821 billion
– 41 technologies continue NTAP eligibility for FY 2027 under the existing newness policy
– 19 NTAP applications approved to start in FY 2027
– Mandatory participation in the nationalized Comprehensive Care for Joint Replacement (CJR) model begins January 1, 2028
– New MS-DRGs finalized for extensive and complex spinal fusion, hip and knee procedures with periprosthetic joint infection, and cardiac pacemaker revision and device replacement

WHAT THIS ACTUALLY MEANS

The CJR nationalization is not a pilot anymore. It is mandatory, and it is coming January 1, 2028. If your organization has not started modeling episode-based payment risk for joint replacement, the clock is running.

The NTAP pathway change is equally significant. Medical device companies that relied on breakthrough designation as a shortcut to Medicare payment will now have to prove clinical and economic value the old-fashioned way. That changes acquisition timelines for hospitals evaluating these technologies.

⚠️ And the TEAM model updates, including expanded spinal fusion episodes and refined pricing methodologies, mean that bundled payment exposure is quietly growing across specialties.

The real risk here is not the rule itself. It is organizations that assume their compliance teams will catch every implication buried in a final rule of this size. These are structural payment changes, not administrative tweaks.

Healthcare is getting harder to navigate, not easier. The providers who build operational fluency with these rules early will absorb the pressure. The ones who wait will scramble.

👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com